- Antibiotics Unveiled as Potential Life Extenders Aiding Healthier Aging
- NK Cells: Unveiling a Multifaceted Medical Marvel for Stroke Recovery and Beyond
- Japan’s Shift to Regular COVID-19 Vaccination for Elderly
- Active Monitoring vs. Surgery for Moderate Cervical Lesions
- Probiotics Linked to Immune Suppression and Tumor Growth
- FDA Investigates T-Cell Malignancy Risk in CAR-T Cell Therapy
Kangtai completed the 1st step for vaccine COVID-19 Delta variant vaccine, successfully isolated COVID-19 Delta variant strain
Kangtai completed the 1st step for vaccine COVID-19 Delta variant vaccine. The Delta mutant strain is the main mutant strain currently spreading global COVID-19 pneumonia.
Good news came from Kangtai Biotech (300601.SZ) on August 5th. The company has made important progress in its vaccine research and development project for the new coronavirus mutant. It has successfully isolated multiple monoclonal strains of Delta mutant strains. The follow-up will be strict According to the quality requirements of human vaccines, the virus strains are evaluated, and the vaccine strains are screened to prepare for the production of inactivated COVID-19 vaccines against the Delta mutant strain.
Boosted by this, the share price on the secondary market of Kangtai Biotechnology rose 14.16% on the same day.
From the isolation of the virus strain to the preparation of a vaccine, what steps need to go through?
According to the relevant person in charge of Kangtai Biology, in order to isolate the “Delta strain”, the company has conducted active surveillance and epidemiological investigations in some countries and regions around the world, collected multiple pathogenic samples, and identified some patients with positive infections. And on the basis of testing, the strain was finally isolated. “After we have the seed strain of the vaccine, we still need to cultivate it before it can become a vaccine strain. Through the vaccine strain, we can prepare a vaccine.”
However, the relevant person in charge of Kangtai Biology said that there is still a process to make a vaccine. “After the vaccine seed strain comes out, it needs to be cultivated by the cell strain to obtain the real vaccine strain. This process takes one month. After the vaccine strain is obtained, a series of inspections and tests are required to pass the identification. Departmental identification, etc., after the candidate inactivated vaccine is made, it still needs to pass the first, second, and third clinical verifications, and then the vaccine can be marketed after approval.”
It is worth mentioning that the research and development process of inactivated virus vaccines is mainly through culturing the virus on the cell matrix, and then using physical or chemical methods to kill the infectious virus while maintaining the integrity of its antigen particles, so that It loses pathogenicity and retains antigenicity. Inactivated vaccines can be composed of whole viruses or bacteria, or their split fragments to form split vaccines.
According to a study by the World Health Organization, compared with other non-VOC and older virus strains, the transmission rate of Delta virus has nearly doubled, and the incubation period and passage interval have been shortened. If there is no strong prevention and control measures to intervene, Without vaccine immunization to stop the spread, the speed of the epidemic will be very significant.
Some data show that vaccines already on the market can still effectively fight the virus. However, the scientific community still dare not take it lightly, and pharmaceutical companies are still intensively developing new vaccines and therapeutic drugs.
Prior to Kangtai Bio, in July this year, BioNTech announced that the company and its partner Pfizer are cooperating to develop an improved vaccine against the full-length spike protein of the delta mutant strain. The first batch of mRNA vaccines for testing have been located in BioNTech. The factory in Mainz, Germany, started production, and clinical trials are expected to begin in August after obtaining regulatory approval.
Over the past year or so, scientists around the world have continuously deepened their understanding of the new coronavirus, and these new understandings also need to be further applied to vaccine development.
Regarding how to improve the development of the COVID-19 vaccine, there are currently many directions that can be explored:
The first is to develop enhanced needles and develop enhanced needle products on the basis of existing vaccine products;
The second is to develop a cocktail vaccine, that is, to develop a multi-linked vaccine based on a mixture of new and old strains;
The third is to develop new adjuvant vaccines. Adjuvants refer to substances that can be added to vaccines to enhance the immunogenicity of vaccine antigens. Past vaccine development experience shows that adjuvants play a very important role in the success of vaccine products;
The fourth is to develop a broad-spectrum vaccine. Although the new coronavirus is mutating, some of the virus’s antigens in conserved regions are unchanged, and a universal vaccine can be developed for these conserved regions.
In addition to vaccines, some pharmaceutical companies are also developing therapeutic drugs that can combat delta.
On August 5th, China Junshi Biotech was informed that the company will file a clinical application for broad-spectrum neutralizing antibody drugs that can cover multiple variants such as Delta in the near future.
At the same time, recently, the research team of SINOPHARM China Biosciences Yang Xiaoming recently discovered effective monoclonal antibodies against delta variants. Among them, the RBD epitope recognized by the most active antibody 2B11 is highly overlapping with the binding site of ACE2, which can effectively block The new coronavirus binds to ACE-2 on the cell surface, thereby preventing it from infecting cells.
SINOPHARM said through its official microblog that the clinical application of the 2B11 antibody is currently progressing in an orderly manner, hoping to be used as soon as possible in the prevention and control of related COVID-19 epidemics in China.
(source:internet, reference only)